Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NeoGenomics, Inc. is a specialized oncology diagnostics company operating within the clinical laboratory testing, precision medicine, and biopharmaceutical services industries. The company focuses on cancer-related genetic, molecular, and pathology testing that supports oncologists, hospitals, and pharmaceutical companies in diagnosing cancer, selecting targeted therapies, and monitoring disease progression. Its core offerings include anatomic pathology, molecular diagnostics, cytogenetics, next-generation sequencing (NGS), and liquid biopsy-based testing.
The company generates revenue primarily through clinical testing services ordered by healthcare providers and through advanced diagnostic and laboratory services provided to biopharmaceutical companies supporting drug development and clinical trials. NeoGenomics is positioned as a pure-play oncology diagnostics provider with an integrated testing platform and large-scale laboratory infrastructure. Founded in 2001, the company has evolved through organic expansion and acquisitions into one of the largest independent oncology-focused testing laboratories in the United States, completing its transition to a publicly traded company in 2012.
Business Operations
NeoGenomics operates through two primary business segments: Clinical Services and Advanced Diagnostics. The Clinical Services segment provides routine and complex cancer testing services to community hospitals, academic medical centers, and oncology practices, generating the majority of company revenue through test volume and reimbursement-based payments. The Advanced Diagnostics segment serves biopharmaceutical companies by supporting clinical trials, companion diagnostics development, and translational research, with revenue derived from contracted laboratory services.
The company conducts operations primarily through NeoGenomics Laboratories, which manages its CLIA-certified and CAP-accredited laboratory network, and InVisionFirst, its liquid biopsy testing platform. NeoGenomics controls proprietary testing workflows, validated assays, and laboratory automation infrastructure. Its operations include domestic laboratory facilities and collaborative relationships with pharmaceutical and biotechnology companies, although it does not disclose material joint ventures.
Strategic Position & Investments
NeoGenomics’ strategic direction centers on expanding its advanced molecular and genomic testing capabilities, increasing biopharma services revenue, and improving operational efficiency. Growth initiatives include investment in NGS platforms, liquid biopsy technologies, and informatics systems designed to support large-scale clinical trials and precision oncology programs. The company has also focused on expanding test menus aligned with targeted and immuno-oncology therapies.
Historically, NeoGenomics has pursued selective acquisitions to expand technical capabilities and geographic reach, although no transformative acquisitions have been announced recently. Its strategic investments emphasize oncology-specific innovation rather than diversification outside cancer diagnostics. Emerging areas of focus include minimal residual disease testing, comprehensive genomic profiling, and data-driven diagnostic services, though the commercial scale of these initiatives continues to evolve.
Geographic Footprint
NeoGenomics is headquartered in the United States, with its principal executive offices in Florida. The company operates a network of clinical laboratories across the United States, enabling nationwide service coverage for oncology practices and hospitals. These facilities support both high-volume clinical testing and specialized molecular diagnostics.
Internationally, NeoGenomics maintains a limited but strategic presence, including laboratory operations and commercial activities in Europe and collaborations that support global pharmaceutical clinical trials. While the majority of revenue is generated domestically, the company’s advanced diagnostics services extend its operational influence across North America and Europe, particularly within multinational biopharmaceutical research programs.
Leadership & Governance
NeoGenomics is led by an executive team with experience in diagnostics, life sciences, and healthcare services, emphasizing operational discipline, customer-centricity, and scientific rigor. Leadership has articulated a strategic vision focused on becoming a preferred oncology diagnostics partner for both healthcare providers and biopharmaceutical companies.
Key executives include:
- Chris Smith – Chief Executive Officer
- Jeff Sherman – Chief Financial Officer
- Douglas VanOort, MD – Chief Medical Officer
Information regarding the company’s original founder and certain historical leadership roles is inconsistent across public disclosures; data inconclusive based on available public sources.